Dr.Kariofyllis Karamperis | Pharmacogenomics | Best Researcher Award

Dr Kariofyllis Karamperis University of Patras, Greece

Kariofyllis Karamperis is a highly qualified researcher in the fields of pharmacogenomics, population genetics, and personalized medicine. He holds a PhD from the University of Patras, where he has excelled academically, receiving an “Excellent” grade for his doctorate. His educational background includes a Master’s Degree in Molecular Pharmacology and a Bachelor’s Degree in Biomedical Sciences.

Publication Profile

scholar

orcid

Strengths for the Best Researcher Award

1. Innovative Contributions: The individual has made significant contributions to the field of pharmacogenomics, advancing our understanding of how genetic factors influence drug response. Their research has the potential to revolutionize personalized medicine, improving patient outcomes.
2. Publication Record: With multiple peer-reviewed publications in high-impact journals, the researcher demonstrates a strong commitment to advancing scientific knowledge. Their work has garnered a substantial number of citations, indicating its relevance and impact in the field.
3. Collaborative Spirit: The researcher has actively participated in multidisciplinary projects and international collaborations, fostering a spirit of teamwork that enhances the quality and reach of their research.
4. Public Engagement: They have contributed to public understanding of pharmacogenomics through presentations and workshops, bridging the gap between scientific research and community health.
5. Leadership in Projects: As a lab manager and early-stage researcher, they have demonstrated leadership skills by guiding projects and mentoring junior researchers, contributing to the development of future scientists.

Areas for Improvement

1. Funding Acquisition: While the researcher has been successful in securing grants, there is an opportunity to expand efforts in obtaining larger-scale funding to support broader research initiatives.
2. Interdisciplinary Integration: Further integrating insights from related fields such as bioinformatics or health economics could enhance their research impact and lead to more comprehensive solutions in personalized medicine.
3. Networking: While collaboration is a strength, building a broader network of industry partnerships could facilitate the translation of research findings into clinical practice and commercial applications.
4. Mentorship Development: Developing structured mentorship programs for students and junior researchers could further enhance their leadership profile and support the next generation of scientists.

📚 Education

Doctorate in Personalized Medicine (PhD)Department of Pharmacy, University of Patras, Greece APR 2020 – JUL 2024
Grade: Excellent.Master’s Degree (MSc) in Molecular Pharmacology Department of Pharmacy, University of Patras, Greece OCT 2016 – NOV 2018 Grade: 9.33/10.Bachelor’s Degree (BSc) in Biomedical SciencesUniversity of West Attica
SEP 2009 – DEC 2015
Grade: 7.56/10.

💼 Experience

Lab ManagerLaboratory of Pharmacogenomics and Individualized Therapy, University of Patras JAN 2024 – PRESENT.Biomodeler Intern Novadiscovery, Lyon, France AUG 2023 – NOV 2023. Visiting Predoctoral Researcher
Institut de Biologia Evolutiva (CSIC -IBE), Barcelona, Spain JAN 2022 – PRESENT.Early-Stage ResearcherGolden Helix Foundation, London, UK JAN 2020 – JAN 2023.Research Technician King’s College London, Department of Twin Research and Genetic Epidemiology FEB 2019 – DEC 2019.

🔧 Skills

Research & Analysis: Population Genetics, Genomics, Pharmacogenomics.Technical Proficiencies: Geographic Information Systems (GIS), Data Visualization.Languages:Greek (Native),English (B2),Spanish (A2).

🎤 Invited Speaker

TranSYS Conference: “Precision Pharmacogenomics for Europe’s Future Health”.ESPR Conference: “Population Pharmacogenomics and its Clinical Impact”.Golden Helix Summer School: “Economic Evaluation in Genome-based Therapeutic Interventions”.

🏆 Grants & Funding

SafePolyMed: EU Horizon 2020, Grant No: 82155.PharmGenHub: EU Horizon 2020, Grant No: 82159.TranSYS: EU Horizon 2020, Grant No 860895.

 

Publication Top Notes

• Title: A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
  Authors: JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, …
  Year: 2023
• Title: Economic evaluation in psychiatric pharmacogenomics: a systematic review
  Authors: K Karamperis, M Koromina, P Papantoniou, M Skokou, F Kanellakis, …
  Year: 2021

 

• Title: Genome-based therapeutic interventions for β-type hemoglobinopathies
  Authors: K Karamperis, MT Tsoumpeli, F Kounelis, M Koromina, C Mitropoulou, …
  Year: 2021

 

• Title: Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study
  Authors: MI Koufaki, V Fragoulakis, X Díaz-Villamarín, K Karamperis, A Vozikis, …
  Year: 2023

 

• Title: Adoption of pharmacogenomic testing: a marketing perspective
  Authors: MI Koufaki, K Karamperis, P Vitsa, K Vasileiou, GP Patrinos, …
  Year: 2021

 

• Title: Clinical implementation of preemptive pharmacogenomics in psychiatry
  Authors: M Skokou, K Karamperis, MI Koufaki, EE Tsermpini, MT Pandi, …
  Year: 2024

 

• Title: Toward high-throughput fungal electroculturomics and new omics methodologies in 21st-century microbiology and ecology
  Authors: A Stathoulias, A Milioni, S Kritikou, A Karmakolia, S Goudoudaki, …
  Year: 2020

 

• Title: Costing methods as a means to measure the costs of pharmacogenomics testing
  Authors: S Siamoglou, K Karamperis, C Mitropoulou, GP Patrinos
  Year: 2020

 

• Title: Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients
  Authors: A Stratopoulos, A Kolliopoulou, K Karamperis, A John, K Kydonopoulou, …
  Year: 2019

Conclusion